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BACKGROUND. Failure of cancer immunotherapy is essentially due to immunological
tolerance to tumor-associated antigens (TAAs), as these antigens are also expressed in healthy
tissues.
METHODS. Here, we used transgenic adenocarcinoma of mouse prostate (TRAMP) mice,
which develop lethal prostate cancer due to prostate-specific expression of SV40 T antigen (Tag),
to evaluate effects of prostatic transformation on oncogene TAA-specific tolerance and to test
the possibility of breaking such tolerance using a modified recombinant vaccinia virus.
RESULTS. We showed that Tag expression in TRAMP mice is uniquely extra-thymic, and
levels of prostatic Tag expression positively correlate with malignant transformation of the
prostate. Yet, young tumor-free TRAMP mice were tolerant to Tag antigen. We therefore
attempted overcoming such peripheral oncogene-specific T cell tolerance through immuniza-
tion with a vaccinia construct encoding Tag immunogenic epitopes. This vaccination modality
showed that oncogene-specific tolerance was successfully overcome by effective in vivo
priming of Tag-specific cytotoxic T cells (CTLs). However, this was restricted to young TRAMP
mice. Tag-specific CTL from ‘‘tumor naı̈ve’’ young TRAMP mice showed significant anti-tumor
efficacy in vivo by eliminating established heterotopic prostate tumors and prolonging survival
in SCID mice harboring Tag-expressing tumors. In contrast, older TRAMP mice with
established prostate tumors exhibited oncogene-specific tolerance as evidenced by failure to
generate Tag-specific CTL following Tag-specific immunization.
CONCLUSIONS. Peripheral tolerance can be overcome for effective anti-tumor therapy
following oncogene-specific immunization. However, this ability to elicit oncogene-specific
CTL is impeded in the tumor-bearing host, in the context of increased oncogene expression
associated with tumor progression. Prostate 68: 715–727, 2008. # 2008 Wiley-Liss, Inc.
KEY WORDS: prostate cancer; peripheral tolerance; recombinant vaccinia
INTRODUCTION
Central immune tolerance plays a critical role in
preventing autoimmune diseases by depleting poten-
tially self-reactive lymphocytes from the T cell reper-
toire. However, as most tumor-associated antigens
(TAAs) can also be found in normal tissues, T cell-
mediated response to tumors is often impeded by T cell
tolerance to TAAs, leading to malignant transforma-
tion and aggressive tumor growth [1–5]. Therefore,
breaking tolerance to TAAs represents the principal
challenge in developing effective anti-tumor immuno-
therapy [6].
Recent reports showed that immunization of
animals using T cell-dependent tumor antigen-specific
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vaccines, such as recombinant vaccinia virus and
whole-cell vaccines, has proved effective at eliciting a
protective response in TAA tolerant transgenic hosts
against autologous tumor challenge [7–11]. Likewise,
although not being able to achieve a complete eradi-
cation of spontaneous tumors, some T cell-mediated
vaccines sufficiently delay the onset of primary tumors
[8,9]. For prostate cancer immunotherapy, irradiated
whole cell-based tumor vaccines have shown some
potential in controlling heterotopic tumor growth in
non-transgenic mice [12]. Also, using prostate-specific
antigen (PSA) transgenic mouse as a model, Wei et al.
[13] have demonstrated that tumor-infiltrating lympho-
cytes (TILs) were able to lyse PSA-expressing tumor
targets in vitro.
In transgenic adenocarcinoma of mouse prostate
(TRAMP) mice, the oncogenic simian virus large
T antigen (SV40 Tag) is expressed specifically in
the prostate in an androgen-dependent fashion, lead-
ing to lethal prostate cancer in older mice [14,15]. The
striking resemblance between the TRAMP mouse
model and prostate cancer progression in humans
provides a unique pre-clinical model for prostate
cancer therapy. Although previous works [16,17] have
reported that therapy with antibodies to CTLA-4
effectively inhibited the outgrowth of transplantable
tumors as well as orthotopic prostate tumors in
TRAMP mice, the lack of evidence of complete
eradication of the Tag oncogene and the partial
destruction of normal prostatic epithelium clearly
elucidates the need for tumor antigen-specific immu-
notherapy. We have previously reported that a safety-
modified recombinant vaccinia virus, vac-mTag, is able
to elicit SV40 Tag-specific CTL activity and protect non-
transgenic mice against Tag-expressing tumors as well
as treat pre-established Tag-expressing microscopic
tumors [18]. Here, we first determined whether extra-
thymic expression of the oncogenic Tag results in
peripheral tolerance in TRAMP mice. Studies were
then undertaken to evaluate the ability of vac-mTag to
break tolerance in TRAMP mice by inducing Tag-
specific CTL activity. Finally, we conducted experi-
ments to assess the efficacy of adoptive transfer of
vac-mTag-elicited Tag-specific CTLs in the treatment
of heterotopic and orthotopic tumors in vivo.
MATERIALS ANDMETHODS
Cell Lines
B6wt19 (provided by S. Tevethia, Pennsylvania
State University College of Medicine, Hershey, PA)
and mKSA (provided by J. Butel, Baylor College of
Medicine, Houston, TX) are SV40 Tag-expressing cell
lines of H-2b and H-2d haplotype, respectively. RM-1
(provided by T. Thompson, Baylor College of Medi-
cine, Houston, TX) is a prostate cancer cell line with
H-2b haplotype that lacks Tag. NK sensitive YAC-1 cell
line was obtained from the American Type Culture
Collection (Manassas, VA). All these cell lines were
maintained in DMEM (Life Technologies, Inc., Gai-
thersburg, MD) supplemented with 100 U of penicillin,
100 mg of streptomycin per ml, and 10% fetal bovine
serum (Life Technologies, Inc.) at 378C and 5% CO2.
Mouse T cell lymphoma line E22 (H-2b) and colon
carcinoma cell line CT26.CL25 (H-2d) (kindly provided
by Dr. Nicholas Restifo at NCI) express b-galactosidase
and were maintained in complete medium containing
400 mg/ml G418.
Animals
Six- to 8-week-old male C57BL/6 mice were pur-
chased from Harlan Sprague–Dawley, Inc. (Indiana-
polis, IN). C57Bl/6-Prkdc (SCID) mice were purchased
from the Jackson Laboratories (Bar Harbor, ME). The
transgenic adenocarcinoma of the mouse prostate
(TRAMP) mice were described previously [14] and
maintained by our laboratory personnel. In this study,
the transgenic mice were all hemizygous (rPB-Tagþ/)
progeny of TRAMP 4741, a progeny of founder mouse
8247 which had been previously provided by
Dr. Greenberg (Baylor College of Medicine, Houston,
TX). The transgenic colony was maintained in the
C57BL/6 strain, with transgene carriers mating to
C57BL/6 breeders to consistently yield hemizygous
progeny. Genotyping was performed via Tag-specific
PCR [15]. All experiments were approved by the
University of Michigan Committee on Use and Care
of Animals and conducted in accordance with the NIH
Guide for the Care and Use of Laboratory Animals.
Hematoxylin-Eosin Staining
Histological analysis was performed on normal pro-
state tissue and prostate tumors. Tissues collected
at necropsy were fixed in 10% (vol/vol) buffered
formalin, transferred to 70% (vol/vol) ethanol, em-
bedded in paraffin, sectioned at 5 mm and stained with
hematoxylin/eosin.
Immunohistochemistry
TRAMP prostates were frozen upon necropsy
in Optimal Cutting Temperature (OCT) compound
(Sakura Finetek, Torrance, CA) and sectioned at 5 mm.
Biotin-conjugated antibodies (BD PharMingen, San
Diego, CA) against mouse CD3 (1:1,200), CD4 (1:800),
or CD8 (1:1,200) were used to stain T lymphocytes.
ExtrAvidin-peroxidase (Sigma, St. Louis, MO; 1:100)




Construction of Recombinant Vaccinia
Encoding an SV40 Tag Fragment
The recombinant vaccinia encoding a SV40 Tag
fragment (mTag) was constructed as described pre-
viously [18]. Briefly, vac-mTag was generated by
homologous recombination in BSC-1 cells transfected
with pSC65-mTag, with the recombinant BSC-1 plaques
identified by immunocytostaining with Tag-specific
monoclonal antibody Pab204 (provided by Dr. J. Pipas,
University of Pittsburgh, PA) as previously described
[18].
ReverseTranscription-Coupled PCR
Total cellular RNA was extracted from prostates
of normal C57BL/6 or TRAMP mice using RNAzol B
(Tel-Test, Friendswood, TX) and quantified by spectro-
photometry. Reverse transcription was performed
using the Promega Reverse Transcription System
(Promega Corp., Madison, WI). PCR amplification
was performed with 50 (50-TGGTTCTACAGGCTCTG-
CTGAC-30) and 30 (50-CCAATCTCTCTTTCCACT-
CCAC-30) Tag primers. Electrophoresis of PCR
products was run on 1% agarose gels (Boehringer
Mannheim, Indianapolis, IN), and visualized with
ethidium bromide. b-actin or b-globin were used as
internal controls for the loading.
Southern Blot Analysis
Plasmid rPB-Tag (kindly provided by Dr. Norman
Greenberg, Baylor College of Medicine, Huston, TX)
[14] was used as template for making a Tag cDNA
probe by PCR. PCR amplification was performed with
50 (50-CCGGTCGACCGGAAGCTTCCACAAGTGCA-
TTTA-30) and 30 (50-CTCCTTTCAAGACCTAGAAGG-
TCCA-30) Tag primers and digoxigenin (DIG) coupled
dUTP using DIG high prime DNA labeling and
detection starter kit II (Boehringer Mannheim). Ten
micrograms of RT-PCR product (above) was loaded
into each lane for Southern blot analysis. The 442bp
DIG-labeled PCR product was then hybridized to
membrane blotted nucleic acids according to the
manufacturer’s protocol.
Western Blot Analysis
Tissues were rinsed with PBS, and homogenized
with a manual homogenizer (Thomas, Philadelphia,
PA), and then resuspended in protein lysis buffer
(5 mM Tris, 120 mM NaCl, 0.5% IGEPAL, Sigma) with
protease inhibitors phenylmeth-ylsulfonyl fluoride,
leupeptin, and aprotinin (Boehringer Mannheim). The
suspension was then sonicated at 23 kHz for 5 sec
bursts (Microson Ultrasonic cell disrupter, Heat Sys-
tems, Inc., Farmingdale, NY) and centrifuged at 14,000g
for 15 min at 48C. Protein concentration in the super-
natant was calculated using the Bio-Rad protein assay
kit (Bio-Rad Laboratories, Hercules, CA). Forty micro-
grams of protein were separated using an 8% Tris–
Glycine gel run at 125 V for 2 hr and transferred to
nitrocellulose at 25 V for 2 hr (Novex Xcell IITM system,
Novex, San Diego, CA). After blocking with 5% milk in
Tris-buffered saline containing 0.1% Tween-20 (TBS-T)
for 1 hr at room temperature, the membrane was
incubated with a Rabbit-Polyclonal anti-Tag antibody
(1:5,000; provided by Dr. Janet Butel, Baylor College of
Medicine, Houston, TX) at 48C in 1.5% milk in TBS-T
overnight. Following three washes in TBS-T, the
membrane was incubated with HRP-conjugated don-
key anti-rabbit IgG antibody (1:5,000; Jackson Immu-
noResearch Laboratories, Inc., West Grove, PA) for
1.5 hr at room temperature, and visualized using ECL
detection reagents (Amersham, Arlington Heights, IL).
SV40 Tag-Specif|c
CytotoxicT-Lymphocyte (CTL) Activity
Splenocytes from C57BL/6 or TRAMP mice were
harvested 3 weeks after intravenous (i.v.) injection with
either vac-mTag or a control vaccinia rVV-b-gal at
107 pfu/mouse. CTL activity was evaluated by 51Cr
release assay after 1 week of splenocyte stimulation
with either mitomycin C (Sigma)-treated syngeneic
Tag-expressing tumor cells or b-galactosidase peptide
and 10 U/ml rIL-2 in vitro. 51Cr-labeled target cells
were incubated with splenocytes at ratios of 33, 11, and
3.7 for 4 hr, and lysates were harvested and analyzed
as described previously [18]. Percent specific lysis
was calculated from triplicate samples as follows:
[(experimental cpm spontaneous cpm)/(maximal cpm
spontaneous cpm)] 100. Data included in this report
represent all assays in which spontaneous release of
labeled target cells was less than 20% of maximal
release, and standard deviation of triplicate values
were less than 15%. Similar experiments were repeated
at least three times.
HeterotopicTransplantableTRAMPProstateTumor
TRAMP mouse #870 was an offspring of a hetero-
zygous female TRAMP (#465) and a non-transgenic
C57BL/6 male mouse. Its Tag-positive genotype was
tested by Tag PCR. Primary prostate tumor was
isolated aseptically from TRAMP mouse #870 at
31-week of age upon death and rinsed in sterile PBS.
The Tumor was then cut into small chunks of 3–4 mm
in diameter. C57BL/6, TRAMP, and SCID mice were
anesthetized with sodium pentobarbital (60 mg/kg)
intraperitoneally (i.p.). A small cut was made on the
skin of the recipient mouse on its right flank. A tumor
chunk was inserted underneath the skin through the
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cut. The incision was then stapled with a sterile
AUTOCLIP applier (Becton Dickinson, Sparks, MD).
Two weeks later, the clip was removed with an
AUTOCLIP remover (Becton Dickinson, MD). Tumor
growth was monitored three times a week. Western
blot analysis was performed to confirm the expression
of Tag by the 870 tumor chunks.
AdoptiveTransfer
For immunotherapy of Tag-expressing hetero-
topic tumors in vivo, splenocytes from vac-mTag-
immunized 2-month-old TRAMP mice or V69-immu-
nized age-matching C57BL/6 mice were stimulated
in vitro with mitomycin C-treated B6wt19 cells and
10 U/ml rIL-2 for 1 week. TRAMP mice-derived Tag-
expressing prostate tumor chunks were implanted
subcutaneously (s.c.) into SCID mice 2 days before
adoptive transfer. Ten million CTLs were collected
from culture and injected i.v. to each tumor-bearing
SCID mouse followed by 5 days of rIL-2 therapy
(30,000 IU/ml, i.p., twice a day). For therapy of
orthotopic prostate tumors, splenocytes from vac-m
Tag-immunized young tumor-free TRAMP mice and
C57BL/6 mice, or control vaccinia V69-immunized
C57BL/6 mice were stimulated in vitro with mitomycin
C-treated B6wt19 cells and 10 U/ml rIL-2 for one week.
Four- to 5-month-old TRAMP mice were given 107 Tag-
specific CTLs each through tail vein injection followed
by 5 days of rIL-2 therapy (30,000 IU/ml, i.p., twice
a day). A second dose of CTL adoptive transfer was
given 8–9 weeks after the first treatment. Tumor
growth and related death in all recipient mice were
monitored two to three times weekly by an individual
who was blinded to the immunization status.
FACS Analysis
Splenocytes from either vac-mTag- or V69-
immunized C57BL/6 and TRAMP mice were cultured
with mitomycin C-treated B6wt19 tumor cells and
10 U/ml rIL-2 for 7 days in vitro. Single cell suspension
was obtained from cell culture and washed twice with
PBS supplemented with 0.1% bovine serum albumin
and 0.1% sodium azide. One million cells were
incubated with 0.5 mg of a FITC-conjugated anti-CD8
antibody and PE-conjugated anti-CD25 antibody
(BD PharMingen) in a final volume of 50 ml at 48C for
30–40 min. A total of 10,000 viable cells were analyzed
per sample in a FACScan flow cytometer (Becton
Dickinson, Sunnyvale, CA).
Statistical Analysis
Statistical significance for survival data was eval-
uated by Kaplan–Meier plots and logrank analysis was
performed with Statistica software (StatSoft, Inc.,
Tulsa, OK).
RESULTS
Characterization of SV40 Tag Expression
Pattern inTRAMPMice
We first sought to characterize patterns of SV40 Tag
expression as TRAMP mice age and undergo malignant
prostate transformation. To this aim, protein lysates
were prepared from prostates of both non-transgenic
B6 and TRAMP mice. Western blot analysis of Tag
using mouse prostate tissue lysates showed that
TRAMP mice (748 and 3512) with palpable prostate
tumors exhibit significantly higher levels of Tag
expression compared to cancer-free TRAMP mice
(2-month-old mice 3191 and 3192; Fig. 1A). Low levels
of constitutive Tag transcripts were detectable by RT-
PCR followed by Southern blot in both 6-month-old
cancer-bearing and 2-month-old cancer-free TRAMP
mice (Fig. 1A). These results suggest that malignant
prostate transformation is associated with increased
level of Tag oncogene expression in TRAMP prostates.
We then evaluated relative central (thymic) and
peripheral (prostatic) expression of SV40 Tag in
TRAMP mice. Total RNA was extracted from the
thymus and prostates of both young and old TRAMP
and non-transgenic C57BL/6 mice. SV40 Tag tran-
scripts were not detected by RT-PCR in neither TRAMP
nor B6 thymi, irrespective of their age (Fig. 1B).
In contrast, prostates from both 2- and 6-month-old
TRAMP mice expressed Tag whereas age-matched
C57BL/6 control mice did not (Fig. 1B). This result is
consistent with a previous report where Tag transcript
was only detectable in dorsal and ventral prostate
tissue in TRAMP mice [14]. Therefore, the tissue
distribution of the androgen-responsive rat probasin
promoter (rPB)-controlled SV40 Tag in the TRAMP
mice is restricted to the prostates.
Evidence for Age-Independent Peripheral
Tolerance toTag inTRAMPMice
To more directly evaluate tolerance to Tag onco-
gene in TRAMP mice, we compared engraftment of
Tag-expressing prostate tumors in control C57BL/6,
TRAMP, and B6 SCID mice. While tumor engraftment
failed in 7 out of 8 C57BL/6 mice, 12 out of 13 SCID mice
developed palpable subcutaneous tumors (Table I).
Surprisingly, all 5 old (>4-month-old) as well as 12
juvenile (<2-month-old) TRAMP mice developed sub-
cutaneous tumors (Table I), suggesting that TRAMP
mice develop tolerance to Tag oncogene regardless of
their age and the status of prostate transformation.
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vac-mTag Does Not Induce Prostate Inflammation
Having established the correlation between pro-
static expression of Tag oncogene and tumor growth,
and the tolerance to Tag oncogene in TRAMP mice, we
subsequently addressed the possibility of breaking
tolerance to Tag by immunizing mice with a safety
modified recombinant vaccinia virus, vac-mTag. A
unique safety modified fragment of Tag cDNA encod-
ing the five H-2b-restricted immunogenic epitopes was
introduced into the vaccinia virus through homologous
recombination to generate vac-mTag [18]. Because
previous reports regarding inflammatory damage that
can take place in the prostate following immunizat-
ion against prostate-specific antigens remain contro-
versial [19–22], we first examined mouse prostates
for prostatic lymphocyte infiltration and autoimmune
prostatitis following immunization with vac-mTag.
Histopathologic analysis showed no significant inflam-
mation in the prostates of 2-month-old TRAMP mice
after immunization with vac-mTag (Fig. 2B) as com-
pared to vac-mTag immunized C57BL/6 prostates
(Fig. 2A) or control vaccinia immunized TRAMP pro-
states of the same age (Fig. 2C). In addition, although
histochemistry of the prostates from 6-month-old
TRAMP mice showed high grade, poorly differentiated
unstructured prostate carcinoma (Fig. 2F), immuniza-
tion with vac-mTag did not cause any significant
inflammatory infiltrates (Fig. 2E), similar to what we
observed in prostates of vac-mTag immunized C57BL/
6 mice of the same age (Fig. 2D). Further evidence was
obtained by immunohistostaining with anti-CD3, -CD4,
or -CD8 antibodies, pointing to the absence of any signi-
ficant T lymphocyte infiltrates in the TRAMP prostates
following vac-mTag immunization (data not shown).
The Abilityof vac-mTag to Elicit Tag-Specif|c
CTLIs Limited toTumor-Free Mice
We next tested the interference of prostate malignant
transformation with the ability to induce Tag-specific
CTL activity in TRAMP mice by Tag-specific immuni-
zation. Immunization with vac-mTag was able to
generate a Tag-specific MHC-restricted CTL response
in control C57BL/6 mice, whereas tolerance against
autologous Tag oncogene was evident in 5-month-old
TRAMP mice, as judged by absence of Tag-specific CTL
activity (Fig. 3). Interestingly enough, immunization of
young tumor-free TRAMP mice with vac-mTag prior
to malignant transformation was successful in cir-
cumventing Tag-specific tolerance. The cytolytic activ-
ity against Tag-expressing syngeneic tumor target
(B6wt19, H-2b) in vac-mTag immunized young
TRAMP was significant and comparable to that
achieved by vac-mTag immunized C57BL/6 mice
(Fig. 3). No significant CTL activity was shown against
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Fig. 1. Prostatic and thymic expression of Tag oncogene in aging
TRAMPmice.A:Prostatetissuelysatesof6-month-oldtumorbear-
ingTRAMPmice(748and3512)and2-month-oldtumor-freeTRAMP
mice (3191 and 3192) were assessed for Tag protein expression by
Western blot (upper panel).Western blot was performed using
rabbit anti-SV40 Tag polyclonal antibody (1:5,000). Forty micro-
gramsof totalproteinwas loadedineachlane.TotalRNAextracted
fromthesameTRAMPprostateswereanalyzedforTaggeneexpres-
sion by RT-PCR (lower panel). Southern blot was performed
following RT-PCR using Tag cDNA as probe. Ten micrograms of




prostates and thymus of 2- and 6-month-old TRAMP and non-
transgenic C57BL/6 mice (upper panel). The quality of the total
RNA from tissue was evaluated by b-actin primers in a parallel
RT-PCR reaction (lower panel).One representative out of three
separateexperimentsis shown.
Oncogene-Specif|c Prostate CancerTherapy 719
neither a Tag-negative syngeneic tumor target (RM-1,
H-2b) nor a Tag-expressing tumor target of a different
MHC haplotype (mKSA, H-2d), suggesting that the
CTL response induced by vac-mTag in 2-month-old
TRAMP mice was Tag-specific and H-2b restricted
(Fig. 3). Tag specificity of potentiated tolerance in older
TRAMP mice was evidenced by competent anti-b
galactosidase (a heterologous antigen) responsiveness
induced by rVV-b-gal immunization, excluding the
possibility of global immunosuppression induced by
tumors (Fig. 3). Taken together, these data demonstrate
that the tolerance to autologous oncogene can be
overcome via induction of oncogene-specific CTL by
recombinant vaccinia immunization under conditions
that minimize peripheral expression of the oncogene
tolerogen by the host.
To assess the potential of vac-mTag induced Tag-
specific CTL from young TRAMP mice in treating
heterotopic Tag-expressing tumors in vivo, SCID mice
were implanted subcutaneously with Tag-expressing
870 transplantable TRAMP prostate tumor. Two days
later, CTLs induced by vac-mTag or V69 control
vaccinia immunization of 2-month-old TRAMP mice
or C57BL/6 mice were adoptively transferred to tumor-
bearing SCID mice. As shown in Figure 4, Tag-specific
CTLs from vac-mTag-immunized young TRAMP mice,
but not CTLs from V69-immunized C57BL/6 mice,
were able to both significantly delay the onset of
the implanted Tag-expressing tumors in SCID mice
(Fig. 4A) and prolong the survival of tumor bearing
animals (Fig. 4B). Hence, Tag-specific CTLs induced
with vac-mTag in young TRAMP mice were effective in
treating Tag-expressing heterotopic tumors in vivo.
Vac-mTag-Induced Tag-Specif|c CTLFrom
TRAMPMice Fail to Mount a Response
Against OrthotopicTumors
We further sought to evaluate the efficacy of vac-
mTag-induced Tag-specific CTLs in targeting pre-
established Tag-expressing orthotopic prostate tumors
in TRAMP mice. To this end, we adoptively transfer-
red Tag-specific CTLs from immunized C57BL/6 and
young tumor-free TRAMP mice to 4- to 5-month-old
tumor-bearing TRAMP mice. Although CTLs from vac-
mTag-immunized young TRAMP mice significantly
improved the survival of SCID hosts with heterotopic
tumors (Fig. 4), they were not as effective against
orthotopic prostate tumors in older TRAMP mice
(Fig. 5A). In contrast, Tag-specific CTLs from vac-
mTag-immunized C57BL/6 mice generated an effec-
tive immune response against primary prostate tumors
in almost 30% of the hosts (Fig. 5A). Therefore, we
sought to reassess possible phenotypic differences
between Tag-specific CTLs from C57BL/6 and TRAMP
mice by evaluating CTL surface CD25 expression.
CD25 expression on the CD8þ T cell population
of cultured splenocytes from vac-mTag-immunized
C57BL/6 mice (Fig. 5B, upper panel) was significantly
greater than that from vac-mTag-immunized TRAMP
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TABLE I. TRAMPMice AreTolerantto Engraftmentof Tag-Expressing ProstateTumor Chunks
Non-transgenic mice SCID mice
TRAMP mice
Juvenile (2 months) Mature (>4 months)
Proportion engraftment 1/8 12/13 12/12 5/5
C57Bl/6, SCID, and TRAMP mice of different ages were implanted with chunks of a TRAMP prostate tumor. They were followed for
palpable subcutaneous tumor growth and progression. Numbers indicate proportion of engrafted mice that developed subcutaneous
tumors.
Fig. 2. Immunizationofvac-mTagdidnotinducesignificantinflam-
mation inTRAMP prostates.Two- and 6-month-oldmale C57BL/6
andTRAMPmicewereimmunizedintravenouslywithvac-mTagand
V69.Three weeks later the mice were euthanized, their prostates
removed and fixedwith10% buffered formalin. Paraffin-embedded




Fig. 3. Theabilityofvac-mTagimmunization tobreakTag-specific toleranceinTRAMPmiceisimpededbymalignant transformationandpro-
gressingprostatic tumors.TRAMPmiceof2- and5-monthofageandnon-transgenicC57BL/6micewereimmunizedwith107pfu/mouseofvac-
mTagorrVV-b-gal (controlvaccinia) administeredby tail vein injection.Threeweekspost-immunization, splenocyteswere stimulatedinvitro
witheithermitomycinC-treatedsyngeneicTag-expressing tumorcells forTag-specificCTL,orwithb-galactosidasepeptideforb-galactosidase-
specific CTL. Seven days later, chromiumrelease assay wasperformed to assess cytolyticT cell activity.Tag-expressing B6wt19 (H-2b),mKSA
(H-2d)cells, andTagnegativeRM-1cells (H-2b)wereusedas targets fordetectingTag-specificCTLactivity.Todetectb-gal-specificCTLactivity,
we used b-gal expressing E22 (H-2b) and CT26.CL25 (H-2d), and b-gal negative NK sensitiveYAC-1cells. Spontaneous release of target cells
never exceeded 20%. Individual conditions were performed in triplicate, and standard error at each measurement did not exceed 15%.
Data representingone outof three similar experiments are shown. [Color figure canbeviewedin the online issue,which is available atwww.
interscience.wiley.com.]
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mice (Fig. 5B, lower panel) or from V69-immunized
C57BL/6 mice (data not shown). These results indicate
that the expression of IL-2 receptor is defective in the
CD8þ CTLs from TRAMP mice following immuni-
zation with vac-mTag. More interestingly, C57BL/
6-derived non-transgenic Tag-specific CTLs not only
delayed the initial palpable time of prostate tumors
in significant numbers of the recipient TRAMP mice
(data not shown), but also completely prevented tumor
incidence in 4 out of 13 recipient TRAMP mice tested
(Fig. 5C). Histologic analysis showed that the four long-
term survivor TRAMP mice exhibit entirely normal
prostate histology at 68 weeks of age whereas the rest
of the TRAMP hosts demonstrate prostate cancer or
high-grade prostate dysplasia upon tumor-related
death (Fig. 5C).
Finally, we determined the extent to which Tag-
specific immunotherapy affected the targeted onco-
gene antigen in the prostate. Prostate Tag expression in
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Fig. 4. Tag-specific CTL from in vivo primed TRAMPmice show
Tag-specific anti-tumor efficacy in vivo.Two-month-old TRAMPor
C57BL/6micewere immunizedwith vac-mTag or V69, respectively.
Threeweeks later, their splenocytes were stimulated in vitro with
mitomycinC-treatedB6wt19 cells togenerateTag-specificCTLs for
adoptivetransfer.Twodaysbeforeadoptivetransfer,prostatetumor
chunks ofTRAMPmicewere implanted s.c. into SCIDmice.107Tag-
specificCTLswerethenadoptivelytransferredintotheseSCIDmice
via tail vein injection.Tumor free survival (time to palpable tumor;
A), and overall survival (time to tumor-related death;B) of these
tumor-bearing SCID mice were monitored three times a week
(n¼ 20mice/group;P¼ 0.0037).
Fig. 5. Vac-mTag induced Tag-specific CTL from non-transgenic
mice, but not from TRAMP mice, eradicated Tag-expressing
orthotopic tumors in tolerant TRAMP hosts. 107 vac-mTag- or
V69-induced Tag-specific CTLs were adoptively transferred to
4 ^5 months old TRAMP mice.A: Overall orthotopic tumor-free
survival of theTRAMP hosts was monitored for up to 68 weeks
before the survivor mice were euthanized for further studies
(n¼ 9 ^18 mice/group; P¼ 0.002).B: Two-colored flow cytometry
was performed for the different groups of donor CTLs with FITC-
labeled anti-CD8 and PE-labeled anti-CD25 antibodies. Numbers
indicate mean fluorescent intensity of CD25 staining on gated
CD8þ cells. C: Histopathology studies revealed normal prostate
epithelium (left panel) in four survivorTRAMPmice thatreceived
vac-mTag immunized C57BL/6 CTL whereas others demonstrated
prostate cancer/high grade dysplasia (middle and right panels).
Numbers indicate proportion of mice from each therapy group.
[Color figure canbeviewed in the online issue, which is available at
www.interscience.wiley.com.]
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Tag Western blot and RT-PCR (Fig 6A,B). Interestingly,
neither Tag protein nor Tag transcripts were detectable
in any of the prostates from the long-term survivor
TRAMP mice (Fig. 6A,B, upper panel). This indicates
that malignant epithelial cells expressing the Tag
oncogene in the prostate were successfully targeted
and eliminated by the immune system following
Tag-specific immunotherapy. The genotype of the four
survivor TRAMP mice was reconfirmed by PCR using
tail DNA (data not shown).
DISCUSSION
In the present study, we used a unique transgenic
mouse model of prostate cancer (TRAMP) to determine
the contribution of peripheral (prostatic) expression
of antigen and tumorigenesis toward potentiation and
maintenance of prostatic TAA tolerance, and evaluate
an alternative method of TAA delivery for immuniza-
tion using a TAA-encoding vaccinia virus to circum-
vent this tolerance.
Failure in rejection of Tag-expressing tumor en-
graftments by tumor-bearing old TRAMP as well as
tumor-free juvenile TRAMP mice (Table I) suggests
that minimal levels of Tag expression undetectable by
Western blot in juvenile TRAMP prostates might cause
immune ignorance of Tag-expressing tumors by the
TRAMP hosts.
In TRAMP mice, levels of tolerogen (Tag) expression
increase in concert with cancer progression (Fig. 1). The
dynamic effects of concurrent cancer progression and
increased tolerogen expression on oncogene-specific
tolerance have not been extensively studied. Although
the absence of Tag transcripts in TRAMP mice thymi in
our hands as shown by RT-PCR (Fig. 1) is consistent
with a previous study that demonstrated exclusive
expression of Tag in the prostate [14], it contradicts
another previous work that reported the presence of
Tag RNA transcripts in TRAMP mice thymi [23]. This
contradiction can be reconciled in our study for a
variety of reasons: First, we could not detect any Tag
protein even in the 2-months-old TRAMP prostates
which exhibit evident Tag mRNA transcripts. Presence
of minute amounts of Tag mRNA transcripts in the
thymus might therefore not be able to result in deletion
of Tag-specific CTL through negative selection. Second,
in the transgenic TCR setting, the proportion of CTL
expressing a single Tag-specific TCR is much higher
than that in the absence of transgene-driven TCR, and
the impact of thymic deletion in the transgenic TCR-
bearing mice may be accentuated as compared to
tolerance processes in tumor-bearing mice without
transgenic TCR, as the latter are capable of producing a
broader repertoire of CD8þ T cells. Third, complete
absence of peripheral Tag specific CTLs was shown in
young tumor-free mice (i.e., 25 days), where T cells who
escaped negative selection in the thymus did not have
the chance to encounter their cognate antigen and
proliferate to detectable amounts.
Unlike previous studies that evaluated CD4 T
lymphocyte- and B lymphocyte-driven peripheral
tolerance in autoimmunity [24–28], our study was
primarily focused on induction of cytotoxic T lympho-
cytes that are TAA-specific and may harbor a potential
therapeutic value in anti-tumor immunotherapy. First,
immunization with vac-mTag promptly primed CTL
activity in young tumor-free TRAMP mice (Fig. 3).
Consistent with previous studies [29–34], this result
implies that tumor reactive CTLs were not deleted in
the hosts that were peripherally tolerant to the extra-
thymic antigen. Although these CTLs readily kill Tag-
expressing tumor targets in vitro in a MHC class
I-restricted fashion, they are phenotypically and func-
tionally different from those derived from non-trans-
genic mice. Unlike B6 CTLs, Tag-specific CTLs from
TRAMP mice failed to expand in vitro following
repetitive stimulation with syngeneic tumor cells and
IL-2 (unpublished data). Ohlen et al. [35] reported a
different finding in which they successfully rescued
and expanded the transgenic CTL by in vitro restim-
ulation with syngeneic tumor and IL-2, although
they failed to detect any CTL expansion following
repetitive in vivo stimulation in the tolerant mice.
Our data provide evidence that tumor antigen-specific
CTL precursors do exist in the periphery of tolerant
The Prostate
Fig. 6. Absence of Tag expression in prostates of the long-
term survivor TRAMP mice that received vac-mTag-induced non-
transgenic CTLs.A: Western blot was performed using prostates
from the four long-term survivor TRAMP mice to identify the
expression of the 94 kDaTag. Anuntreated TRAMPprostate and a
Tag-expressing tumorcelllinewereusedaspositivecontrolswhilea
non-transgenicprostatewasusedasnegativecontrol.B:TagRT-PCR
was performed using the same set of prostates as above to deter-
mine the expression of Tag transcript.Genotyping was performed
with tail DNA to confirm theTag-positive identities of the tumor-
free TRAMP mice. b-globin served as internal control for both
RT-PCRandgenotypingPCR.
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tumor-bearing hosts. When properly activated, these
CTLs can recognize the tolerogen and demonstrate
effective cytolytic activity against tumor targets.
Additionally, our findings indicate that the level of
tolerogen plays a pivotal role in determining the depth
of peripheral tolerance against the extra-thymic tumor
antigen [36–38]. Vac-mTag immunization failed to
induce Tag-specific CTL activity in the profoundly
tolerant older TRAMP mice, such lack of responsive-
ness was tumor antigen specific and not driven by the
generalized tumor growth as evidenced by the strong
CTL response to b-gal (Fig. 3).
Breaking tolerance to TAAs in hosts with large
tumor burden proved to be challenging. Tumor cells
and the intratumoral milieu have been shown to
interfere with in vivo function of tumor reactive
lymphocytes [3] by directly acting on T lymphocytes
[39–41] or by compromising antigen processing and
presentation by antigen-presenting cells (APCs)
[42,43]. Additionally, a variety of mechanisms have
been shown to impede immune responses to tumors
(Reviewed in Ref. [44]), such as the release of the
immunosuppressive substances IL-4, IL-6, and IL-10
[45–48], TGF-b [49,50], L-arginine and nitric oxide
[51,52], prostaglandin E2 [53], MUC1 glycoprotein [54],
and PSA [55,56]. Furthermore, it has been reported that
tumor cells express Fas-L and induce CTL apoptosis
through Fas–FasL interaction (reviewed in Refs. [57]
and [58–60]), although this claim remains a subject of
controversy [61].
Although our data did not unravel the potential
mechanisms utilized by Tag-expressing tumors to
escape immune surveillance, the lack of effective CTL
activity following vac-mTag immunization in tumor-
bearing TRAMP mice (Fig. 3), together with the age-
dependent Tag expression in TRAMP mice tumors
(Fig. 1), might suggest that induction of tumor antigen-
specific CTL at an early age when tumor burden is
relatively low might be a key factor for an effective anti-
tumor immunotherapy to take place. This is in line with
two recent reports that demonstrated that early
immunization directed against SV40 Tag can result in
overcoming peripheral T cell tolerance and lead to
extensive control of pancreatic [62] and prostatic [63]
tumor progression in SV40 Tag transgenic mice.
In our in vivo studies, the recombinant vaccinia-
induced Tag-specific CTLs from young TRAMP mice
demonstrated ability to delay the onset and growth of
implanted heterotopic tumors in SCID mice (Fig. 4),
consistent with their Tag-specific cytolytic activity
in vitro (Fig. 3). However, a more effective protection
was accomplished by Tag-specific CTLs derived from
non-transgenic B6 mice, as they not only effectively
controlled the outgrowth of heterotopic tumors in SCID
hosts (data not shown), but also eradicated orthotopic
tumors in 4 out of 13 TRAMP prostates tested (Fig. 5A).
Histologic analysis (Fig. 5B), as well as Tag Western blot
and RT-PCR assays (Fig. 5C,D), revealed that the subset
of prostate cells that expressed Tag oncogene was
eliminated by non-transgenic Tag-specific CTL ther-
apy. This corroborates the previous observation by
Granziero et al., who performed an adoptive transfer of
memory T cells that succeeded in preventing tumor
development in TRAMP mice without damaging the
prostate tissue. Invasion of the stroma by tumor cells
was completely prevented, and the few Tag positive
cells that could still be observed in treated mice were
apoptotic and confined above the basal membrane
either in the epithelium or exfoliating in the gland
lumen [21].
Absence of damaged prostate tissue in this model
[21] is in agreement with our findings and with a recent
work that reported that T lymphocytes specific for a
prostate antigen are capable of inducing inflammatory
infiltration of the prostate without causing pathological
prostate injury [22].
Lack of correlation between in vitro reactivity of
T lymphocytes specific for an oncogene tolerogen and
their anti-tumor efficacy in vivo is well documented
[64–67]. Similarly, adoptive transfer of vac-mTag-
induced CTLs from juvenile TRAMP mice did not
prevent the orthotopic tumor growth in TRAMP
prostates in our hands (Fig. 5A), despite exhibiting
a high killing potential against Tag-expressing
tumor cells in vitro (Fig. 3). Phenotypic analysis of
T lymphocytes revealed that expression of IL-2 receptor
alpha (CD25) was hampered in the CD8þ cell subset
(Fig. 5E), which would subsequently interfere with the
expansion of tumor-reactive T lymphocytes in vivo.
Consistent with this observation, Ohlen et al. have
previously reported that CD8þ T lymphocytes fail to
proliferate in response to a tumor-associated tolerogen
despite their ability to lyse tumor cells and produce
IFN-g. This unresponsiveness was attributed to an
abrogated IL-2 production by CD8þ T cells and their
unresponsiveness to exogenous IL-2 [65]. Others have
reported that partial agonists fail to induce T cell
proliferation, although they do induce cytolysis and
the secretion of at least some cytokines [68,69].
Interestingly, in our hands, the same set of CTLs that
were ineffective in treating orthotopic tumors were
effective in treating pre-established heterotopic tumors
in non-tolerant immunocompromised SCID hosts
(Fig. 4). This suggests that mechanisms other than
down-regulation of CD25 expression by CD8þ T cells
might be involved in skewing the partially activated
CTLs in the Tag tolerant TRAMP hosts towards a
tolerant phenotype.
Taken together, the data presented here corroborate
the persistence of Tag-specific CTLs in TRAMP mice,
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and point to the possibility of activating antigen-
specific CTLs against endogenous Tag-induced pros-
tate tumors. Such activation could be achieved through
vaccination with safety-modified recombinant vaccinia
virus carrying Tag. Nevertheless, generating efficient
CTLs that can benefit anti-tumor therapy requires an
early immunization to avoid peripheral tolerance that
is triggered by tumor antigen encounter.
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